Proposed Change:
Sublingual immunotherapy has been demonstrated to be effective against rhinoconjuctivitis and asthma symptoms. [1] This effectiveness, however, varies depending on the type of allergen. [1] In general, sublingual exposures to grasses, mites, Parietaria, ragweed, cat, olive, birch, and cedar have been shown to reduce symptoms by anywhere from 20-35%. [1] The strongest evidence for the efficacy of sublingual immunotherapy comes from studies that used grass allergens, mite allergens to alleviate allergic rhinitis symptoms, however the strength of symptom relief was still only a modest improvement. [2] The long-term effectiveness and outcomes are still unclear, and there is still work to be done to determine the optimal dosage, regimens, and allergens to get the best results for people. [1]
Proposed Change:
While a number of side effects have been associated with sublingual immunotherapy, serious adverse effects are very rare (about 1.4/100000 doses), and there has not been a reported fatality. [1] There have been a small number of reports of anaphylaxis. [1] The majority of side effects are ‘local’ and usually resolve within a few days. [1] They include swelling of the mouth, tongue or lip, throat irritation, nausea, abdominal pain, vomiting, diarrhea, heartburn, and uvular edema. [1] It is not yet clear if there are any risk factors that might increase a person's susceptibility to these adverse effects. [1] Sublingual immunotherapy appears to be better tolerated than subcutaneous immunotherapy and causes fewer side effects. [1] The safety of sublingual immunotherapy has not been studied extensively in people with chronic immunodeficiency or autoimmune disorders. [1]
{{
cite journal}}
: CS1 maint: PMC format (
link) CS1 maint: unflagged free DOI (
link)
Thanks for sharing your suggestions. The two sources you chose look great. I have a few notes:
Great work so far! JenOttawa ( talk) 15:49, 6 November 2018 (UTC)
Thanks for updating your refs and adding links. JenOttawa ( talk) 11:49, 12 November 2018 (UTC)
Proposed Change:
Sublingual immunotherapy has been demonstrated to be effective against rhinoconjuctivitis and asthma symptoms. [1] This effectiveness, however, varies depending on the type of allergen. [1] In general, sublingual exposures to grasses, mites, Parietaria, ragweed, cat, olive, birch, and cedar have been shown to reduce symptoms by anywhere from 20-35%. [1] The strongest evidence for the efficacy of sublingual immunotherapy comes from studies that used grass allergens, mite allergens to alleviate allergic rhinitis symptoms, however the strength of symptom relief was still only a modest improvement. [2] The long-term effectiveness and outcomes are still unclear, and there is still work to be done to determine the optimal dosage, regimens, and allergens to get the best results for people. [1]
Proposed Change:
While a number of side effects have been associated with sublingual immunotherapy, serious adverse effects are very rare (about 1.4/100000 doses), and there has not been a reported fatality. [1] There have been a small number of reports of anaphylaxis. [1] The majority of side effects are ‘local’ and usually resolve within a few days. [1] They include swelling of the mouth, tongue or lip, throat irritation, nausea, abdominal pain, vomiting, diarrhea, heartburn, and uvular edema. [1] It is not yet clear if there are any risk factors that might increase a person's susceptibility to these adverse effects. [1] Sublingual immunotherapy appears to be better tolerated than subcutaneous immunotherapy and causes fewer side effects. [1] The safety of sublingual immunotherapy has not been studied extensively in people with chronic immunodeficiency or autoimmune disorders. [1]
{{
cite journal}}
: CS1 maint: PMC format (
link) CS1 maint: unflagged free DOI (
link)
Thanks for sharing your suggestions. The two sources you chose look great. I have a few notes:
Great work so far! JenOttawa ( talk) 15:49, 6 November 2018 (UTC)
Thanks for updating your refs and adding links. JenOttawa ( talk) 11:49, 12 November 2018 (UTC)